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Summary
Prostaglandins (PGs) are important mediators of acute and chronic inflammation. The production of PGs in synovial tissues is catalyzed by
an enzyme cascade that includes phospholipase A2s (PLA2s), cyclooxygenases (COXs), and terminal PG synthases. There are two isoforms
of COX expressed in synovial tissues. COX-1 is constitutively expressed in synovia, particularly in synovial lining cells. COX-2, on the other
hand, is localized most strikingly to the vascular endothelial cells, mononucler inflammatory cells, and subsynovial fibroblasts. There are no
significant differences in immunostaining of COX-1 in vivo in inflammatory compared with non-inflammatory arthritis. COX-2 expression is
increased in inflammatory arthritis. In-vitro, COX-2 expression in synovial cells is dramatically increased by proinflammatory cytokines,
phorbol ester, and stimulation of certain cell surface receptors. A number of different transcription factors are likely to be involved in the
up-regulation of COX-2 in synovial tissues. Expression of COX-2 is inhibited by glucocorticoids in synovial cells as in other cell types. Taken
together, these data suggest that COX-2 is likely to be responsible for increased local PG production during inflammation of synovial tissues.
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Synovial tissues from patients with inflammatory arthritis
produce high levels of prostaglandins (PGs).1 PGs mediate
a number of the characteristic features of inflammation, the
concept of which can be broadened to describe the
response of living tissues to injury. By this definition,
inflammation includes not only the cardinal signs of acute
inflammation, but more chronic features such as tissue
breakdown and repair. PGs play a key role in the dilatation
and permeability of small blood vessels that leads to the
development of erythema, warmth, and swelling. PGs also
sensitize peripheral nociceptors to the action of other
mediators which trigger their activity. In rheumatoid arthritis
(RA), acute and chronic inflammation occur together in
synovial pannus. Features of chronic inflammation, includ-
ing altered expression of matrix metalloproteinases and
formation of new blood vessels, are also stimulated by
PGs.1,2 In addition to these pro-inflammatory effects, PGs
also exert immunomodulatory effects on cells of the
immune system, broadly functioning to inhibit neutrophil
and macrophage functions.3
The diverse actions of PGs as mediators of biologic
activity are controlled both by cell type diversity of PG
production via enzyme cascades and the existence of
multiple G-protein linked receptors.4 Release of arachi-
donic acid from the phospholipid membrane by several
types of phospholipase A2s (PLA2s) is followed by metab-
olism to PGH2 by one of two isoforms of cyclooxygenase(COX). Both PLA2 and COX are regulated enzymes that
represent critical control points in the regulation of PG
production. PGH2 is metabolized to active PGs by terminal
synthases, these terminal synthases have cell type specifi-
city and there may be linkages between members of the
PG production enzymatic cascade.5
Another mechanism by which the action of PGs is
regulated occurs at the level of the receptor.6 For example,
PGE , a critical mediator of acute inflammation, mediates2
406its actions through E-type PG (EP) receptors. There are at
least four sub-types of EP receptors, one of which has
three different isoforms. Differing linkages to intracellular
signaling pathways allow for the diversity of cellular
responses to PGE2.
Although all these controls to PG production and action
are likely to act coordinately during inflammation of joint
tissues, this manuscript will focus on COX. The COX
enzymes are targets of pharmacologic action of the non-
steroidal antiinflammatory drugs, and expression of the
COX-2 isoform is inhibited by glucocorticoids. Since these
are widely used and effective treatments for the inflamma-
tion associated with arthritis, understanding the biology of
the COX enzymes in joint tissues will provide a rational
basis for evaluating therapeutic applications of new
antiinflammatory compounds that specifically inhibit
COX-2.COX expression in synovial tissues
Cyclooxygenase (COX) is the multifunctional enzyme
that catalyzes conversion of arachidonic acid to PGH2. Two
isoforms of the COX enzyme have been characterized.
COX-1 is expressed constituitively in most cells. Synovial
tissues express COX-1, particularly in the synovial lining
layer, and there appears to be no difference in COX-1
expression related to the degree of inflammation of the
tissue (Table I).7 COX-2, on the other hand, has highly
restricted expression under basal conditions, but is dra-
matically upregulated during inflammation. Immunostaining
for COX-2 is increased in RA and ankylosing spondylitis as
compared with osteoarthritis (OA).7,8 In inflammatory
arthritis, localization is most striking in vascular endothelial
cells, infiltrating mononuclear inflammatory cells, and
subsynovial fibroblast-like cells.7,8
From what is known of the biology and localization of
COX -1 and COX-2, it might be expected that COX-2 is
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the setting of inflammatory arthritis. In this regard, it is
instructive to discuss those stimuli that increase COX-2
expression, some of which have been directly studied in
synovial cells and others not. Situations in which there is
altered oxidant tone or tissue hypoxia modulate COX-2
expression.9,10 Cytokines, such as interleukin (IL)-1 and
tumor necrosis factor (TNF)-Æ, and growth factors import-
ant in the healing process, such as platelet derived growth
factor, the principal synoviocyte mitogen, increase COX-2
expression.11–13 Glucocorticoids suppress the expression
of COX-2 in all cell types studied.12 In some cell types and
tissues, not cultured synovial fibroblast-like cells, cytokines
such as IL-4, IL-13, and IL-10 also suppress COX-2.12 In
addition, stimulation of cell surface structures, such as
MHC class II on interferon-stimulated synoviocytes,
increases COX-2 expression.14
The promoter of human COX-2 contains multiple binding
sites for transcription factors up-regulated during inflam-
mation. In primary human synovial fibroblast-like cells,
NF-ŒB plays a role in stimulating COX-2 expression.15 This
is potentially important as active NF-ŒB is present consti-
tuitively in RA synovial tissues in vivo.16 Other transcription
factors, particularly c/EBP and members of the AP-1 family
of transcription factors are also likely to play a role in
stimulating COX-2 expression in synovial tissues, since
they are critically important to up-regulated transcription of
COX-2 in many other cell types. In addition, there are
binding sites for the STATs in the COX-2 promoter that may
modulate transcription (unpublished data).Evaluating the role of the COX isoforms in
synovial PG production
As noted above, the increase in local PG production in
inflammatory versus non-inflammatory arthritis is likely to
be due to increased COX-2 expression. Nevertheless,
there is a substantial amount of COX-1 present, particularly
in the synovial lining cell layer. In situations where there is
proliferation of the lining layer, such as RA, there may be
more COX-1 present due to increased cellularity. It must berecalled that there is a substantial amount of sPLA2 present
in rheumatoid synovial fluid that could generate arachidonic
acid substrate for lining cell layer COX-1.17 It is appropriate
to consider whether PGs produced in this fashion might
either contribute to acute inflammation or participate in
anti-inflammatory activity, particularly regarding neutrophil
functions, in arthritis.
There are few in-vivo studies of PG levels in synovial
fluid or COX activity in synovial tissues of arthritis patients
undergoing treatment with COX inhibitors. One study com-
pared synovial fluid PG levels in patients treated with
NSAIDs compared with 6-methylprednisolone.18 This study
demonstrated multiple PG isoforms suggested to have
different cellular sources. NSAIDs caused consistent
reduction of synovial fluid of all PG isoform levels, particu-
larly PGE2. However, glucocorticoid treatment, which is
expected (but not shown in this study) to inhibit COX-2
expression, reduced 6-keto-PGF1Æ, the stable metabolite
of PGI2, levels, but not levels of PGE2 or TXB2. Several
possible explanations for these findings exist, including the
possibility that synovial fluid PG levels reflect the activity of
COX-1 in the synovial lining layer. Measuring tissue COX
activity after treatment with non-specific inhibitors of COX,
specific COX-2 inhibitors, and glucocorticoids may be a
more useful method of assessing the relative importance of
the COX isoforms in inflammatory arthritis.Table I
COX isoforms in synovial tissues
COX-1 COX-2
In vivo
Arthritis types OA, RA, AS AS, RA>OA [7, 8]
mRNA (RA) + + + + + [8]
Immunostaining Lining layer Vascular endothelial cells, infiltrating mononuclear cells,
sublining synovial cells, lining layer [7]
Ex vivo
mRNA, basal + + + + + Crofford, unpublished
Protein, basal + + + + [11]
Regulation, IL-1â — ››› [11]
PMA — ››› [11]
Glucocorticoids — flfl (basal and stimulated) [11]
In vitro (fibroblasts)
mRNA, basal + ± [11, 12, 15]
Protein, basal + — [15]
Regulation, IL-1â — ››› [11, 12, 15]
TNF-Æ — flfl Crofford, unpublished
Superantigen — ››› (IFN-ª-treated cells) [14]
Glucocorticoids — flflfl [11, 12]
IL-4 — « Crofford, unpublishedReferences
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